Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Percutaneous Atherectomy System Treats Peripheral Calcifications

By HospiMedica International staff writers
Posted on 16 Nov 2014
Novel orbital technology removes plaque buildup in peripheral arterial disease (PAD) and critical limb ischemia (CLI) without damaging the soft arterial tissue.

The Stealth 360° Orbital Atherectomy System (OAS) system is intended to treat calcified and fibrotic plaque in arterial vessels by endarterectomy. More...
The system is based on an orbital mechanism of action that protects healthy tissue, while removing even the most difficult to treat plaque. The electrical-powered handle features a power button and speed selection controls positioned for ease of use and greater physician control. The crown, available in sizes of 1.25, 1.50, 1.75, and 2.00 mm, is designed for maximal plaque removal at lower speeds, with a flexible shaft for compromised run-off, vessel bends, or tortuous anatomy.

The orbital system operates by centrifugal force, which causes the crown to rotate at the same time as it advances through the lesion. As crown rotation increases, centrifugal force presses the crown against the plaque and sands it into tiny particles. More than 99% of the particles are smaller than a red blood cell, and they are washed away with the patient’s blood flow. The elastic, more compliant tissue flexes away from the crown and leaves the non-diseased tissue intact. The result is a smooth, concentric and open vessel that appears to be a normal size and allows robust blood flow.

Additionally, by first removing the hardened plaque and changing the compliance of the lesion by atherectomy, clinicians can subsequently perform low-pressure balloon angioplasty, which may reduce the potential for barotrauma to the vessel during the angioplasty procedure. The Stealth 360° Orbital Atherectomy System (OAS) system is a product of Cardiovascular Systems (CSI; St. Paul, MN, USA), and has received the European Community (CE) marking of approval.

“Securing CE mark for Stealth 360° greatly expands our market opportunity and is an important milestone toward benefiting patients in Europe suffering from PAD, especially those with CLI, who have been underserved by other treatment options,” said David Martin, president and CEO of CSI. “A determining factor for CLI is calcium buildup in leg arteries, particularly small vessels below the knee. Our technology, with its unique mechanism of action, has demonstrated it can safely and effectively treat this complex disease, with lasting results.”

PAD is a narrowing of the peripheral arteries due to atherosclerosis, and is most common in the pelvis and legs. The most common symptoms of PAD are cramping, pain, or tiredness in the leg or hip muscles while walking or climbing stairs, which is temporarily relieved by rest. PAD sufferers have four to five times more risk of heart attack or stroke, and if left untreated, it can lead to gangrene and amputation.

Related Links:

Cardiovascular Systems



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.